Enveda's Radical Vision for the Future of Medicine | Viswa Colluru & Pablo Lubroth
Enveda Founder and CEO Viswa Colluru believes we have been looking for new medicines in the wrong places for decades.
In the Season 1 finale of Forecast 2050, I sat down with Viswa and Pablo Lubroth, VP of Special Projects at Enveda, to discuss why 9 in 10 drugs fail in clinical trials despite Big Pharma spending $276 billion in annual R&D, how AI is finally unlocking 99% of nature's chemistry that we've haven't been able to read, why the incentive structure of biotech capital markets is actively bad for patients, why insisting on understanding how a drug works actually slows down drug…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.